Experimental Drug for Bietti’s Crystalline Dystrophy Gets Orphan Drug Designation
Hans / Pixabay

Experimental Drug for Bietti’s Crystalline Dystrophy Gets Orphan Drug Designation

According to a story from BioSpace, the gene therapy company Reflection Biotechnologies Ltd. recently announced that the US Food and Drug Administration (FDA) has given Orphan Drug designation to its…

Continue Reading Experimental Drug for Bietti’s Crystalline Dystrophy Gets Orphan Drug Designation
The First Patient Has Been Dosed on a Study of a Drug For Duchenne Muscular Dystrophy
DarkoStojanovic / Pixabay

The First Patient Has Been Dosed on a Study of a Drug For Duchenne Muscular Dystrophy

The Australian biopharmaceutical company Antisense Therapeutics has announced that the first patient has been dosed on a Phase 2 clinical trial of the investigational drug ATL1102, which is being developed…

Continue Reading The First Patient Has Been Dosed on a Study of a Drug For Duchenne Muscular Dystrophy

A Drug Being Developed to Treat Acute Myeloid Leukaemia Has Been Given a Generic Drug Name

The United States Adopted Name Council, which selects simple, new, and informative generic drug names, has approved ‘Onvansertib’ as the generic name for PCM-075. PCM-075 is an investigational drug that…

Continue Reading A Drug Being Developed to Treat Acute Myeloid Leukaemia Has Been Given a Generic Drug Name